Acelyrin | 10-Q: Q1 2025 Earnings Report
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Lumis Stockholders Approve All Proposals Required To Be Approved In Connection With Pending Merger With ACELYRIN; Merger Is Expected To Close In Q2 2025
Express News | Alumis Inc - Merger Expected to Close in Q2 2025
Express News | ACELYRIN Stockholders Approve Merger With Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
ACELYRIN Stockholders Approve Merger With Alumis To Create Clinical Biopharma Company Dedicated To Innovating, Developing And Commercializing Transformative Therapies For Immune-mediated Diseases >SLRN
WEX, Acelyrin, and More Stocks See Action From Activist Investors -- Barrons.com
Acelyrin Urges Stockholders to Vote for Proposed Merger With Alumis
Acelyrin Gains as Trium Capital Rebuffs M&A Deal With Alumis
Alumis Raises Share Consideration for Acelyrin Acquisition
Express News | Alumis Inc - Expects Runway to Fund Operations Into 2027
Express News | Alumis Inc - ACELYRIN Stockholders to Receive 0.4814 Shares of Alumis per Share
Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement
Express News | Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Insider Stock Sales Shake Up ACELYRIN, INC.
Insider Sale: Chief Executive Officer of $SLRN Sells 17,986 Shares
Acelyrin | 10-K: FY2024 Annual Report
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell
Express News | ACELYRIN Adopts Limited-Duration Stockholder Rights Plan